esmo 2017 hypersensitivity
This site uses cookies. Evaluation of the incidence of carboplatin hypersensitivity in cancer patients. (2001). Educate. The drug or food allergy in 735 patients receiving carboplatin-based chemotherapy. Clin Rev Allergy Immunol. For more detailed information on the cookies we use, please check our Privacy Policy. Monitor. NCT00567190, NCT02402712, NCT01358877, NCT00545688, NCT00976989, NCT02132949, NCT03493854, NCT03674112. The overall safety of desensitization for common chemotherapy drugs and monoclonal antibodies. ESMO 2017 was held in partnership with the European Association for Cancer Research (EACR) in Madrid . This site uses cookies. Necessary cookies enable core functionality. Hypersensitivity & Infusion Reaction Management Author: Updated 2.21.19 Subject: SCC Pharmacy Cancer 19, 12841287. Carboplatin and other paltins such as cisplatin and oxaliplatin reactions include classical symptoms of anaphylaxis with cutaneous, respiratory, cardiovascular, and gastrointestinal symptoms. Drafting of manuscript: Y-HT and W-FC. MeSH In the US, PH FDC SC can be administered by healthcare professionals in patients (pts) homes. van de Loosdrecht, Arjan A. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23, Published in 2020 Ann Oncol (2020)Authors:M.E. Anticancer. In conclusion, in our present population of women with gynecological malignancies treated with platinum-based chemotherapy, 1 in 10 developed carboplatin-related hypersensitivity reactions. Gynecol. 4 - 9 Without premedication, hypersensitivity reactions (HSRs) occurred in 25%-30% of patients in these studies and clinical development of paclitaxel was consequently delayed. Ke. (2009) reported a 3.54% rate of severe carboplatin-related hypersensitivity reactions, which is similar to our rate of 2.2%. Close monitoring is warranted for patients with a history of drug or food allergy, malignant ascites, or cumulative carboplatin dose >4,000 mg. Strategies for preventing carboplatin-related hypersensitivity include reducing the carboplatin infusion rate and employing desensitization protocols with anti-allergy medications. The PAGA project aims to adapt the ESMO Clinical Practice Guidelines by integrating Asian ethnic, scientific, socioeconomic, and local practice characteristics. 24, 46994707. A total of 59 women experienced mild signs and symptoms (grades 1 and 2), including skin rash (69.3%), skin itching (64.0%), facial flushing (56.0%), dyspnea (41.3%), chest pain (25.3%), tachycardia (18.7%), paresthesias (16.0%), abdominal cramping (13.3%), and diaphoresis (12.0%). 66, 730. Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordan on behalf of the ESMO Guidelines Committee These ESMO Clinical Practice Guidelines provide recommendations on the . Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. Table 1. It would be worthwhile to design a perspective trial that could randomize patients with carboplatin hypersensitivity to receive an alternative regimen without carboplatin. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel on patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. Timetrend analyses showed that most events were reported during the first 68 cycles with concurrent chemotherapy, with a decrease in later cycles (except MetaPHER). Zhonghua. doi: 10.1007/s00520-011-1123-y, Gomez, R., Harter, P., Lck, H. J., Traut, A., Kommoss, S., Kandel, M., et al. Cancer 109, 10721078. Here, we retrospectively evaluated carboplatin-related hypersensitivity reactions among patients with gynecological cancer (ovarian, fallopian tube, or primary peritoneal cancer) who received carboplatin-containing regimens at a single medical institute in Taiwan. Here's a summary of the new ESMO guidelines in 5 key areas: . Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? (2011). Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly. Za. Up to 16% of patients with ovarian cancer who undergo treatment with carboplatin-containing regimens experience carboplatin-related hypersensitivity (Markman et al., 1999; Polyzos et al., 2001; Sliesoraitis and Chikhale, 2005). Death from anaphylaxis to cisplatin: a case report. Author Information. For more detailed information on the cookies we use, please check our Privacy Policy. Leuk Lymphoma. Gynecol. TABLE 3 Table 3. Such reactions were scored according to the Common Terminology Criteria for Adverse Events version 4.03, with severity assessed as mild (grades 1 and 2) or severe (grades 3 and 4). All funding for this site is provided directly by ESMO. All funding for this site is provided directly by ESMO. Platinum-based combination chemotherapy is the recommended treatment for platinum-sensitive recurrent ovarian cancer (Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010). There was a striking difference in PFSmedian 16.8 versus 5.6 months, HR 0.52 (highly significant)with the difference in PFS sustained at 12- and 18-month landmarks. Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. (1999). The cumulative incidence of severe carboplatin-related hypersensitivity was 1% after 15 cycles and 2% after 24 cycles, with a plateau beyond this cycle number, and 1% at >7,500 mg and 2% at >12,500 mg, with a plateau beyond this dose (Figures 1A,B). Risk factors for these reactions included advanced disease, serous histological type, malignant ascites, and history of drug allergies. HHS Vulnerability Disclosure, Help J Exp Clin Cancer Res (2011) 30:93.10.1186/1756-9966-30-93 Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. and transmitted securely. This site uses cookies. Int. Int J Med Sci (2011) 8(4):3328.10.7150/ijms.8.332 Gynecol. Cardiopulmonary resuscitation and endotracheal intubation were performed, but the patient finally expired due to respiratory failure. 1; Mandac Smoljanovi, Inga 2. Met Based Drugs (2010) 2010 Available from: Markman M. Toxicities of the platinum antineoplastic agents. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . -, Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, et al. (2009). doi: 10.1002/cncr.21168, Dizon, D. S., Sabbatini, P. J., Aghajanian, C., Hensley, M. L., and Spriggs, D. R. (2002). Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. doi: 10.1007/s00280-009-1159-6, Iwamoto, T., Hirai, H., Yamaguchi, N., Kobayashi, N., Sugimoto, H., and Tabata, T. (2014). Gynecol. ESMO is a Swiss-registered not-for-profit organisation. J. Gynecol. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. doi: 10.7759/cureus.24515. doi: 10.1016/j.ygyno.2006.10.047, Shah, A. C., Minturn, J. E., Li, Y., Belasco, J. Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordanon behalf of the ESMO Guidelines Committee. BRCA1/2 mutation has been reported to correlate with carboplatin hypersensitivity (Altwerger et al., 2017). The site is secure. The cumulative incidence of carboplatin-related hypersensitivity reactions dramatically increased with >8 cycles or dose >3,500 mg. Patients without ovarian cancer were excluded from retrospective analysis of details of hypersensitivity reactions recorded contemperaneously between April 2019 - January 2020 on excel and chemocare (CIS Oncology, Belfast, UK) by the treating practitioner. Check the latest publications and updates here to make sure you dont miss anything. A cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) across all pivotal trials cited in the current EMA P IV/PH FDC SC SmPCs. J. Authors S Rosell 1 , I Blasco 1 , L Garca Fabregat 1 , A Cervantes 1 , K Jordan 2 ; ESMO Guidelines Committee Prevention and Management of Dermatological Toxicities Related to Anticancer Agents: ESMO Clinical Practice Guidelines. Background Hypersensitivity reactions (HSRs) are sometimes associated with the administration of certain cancer drugs. S M S, Naveen NR, Rao GK, Gopan G, Chopra H, Park MN, Alshahrani MM, Jose J, Emran TB, Kim B. 24, 342351. 2022 Mar 30;9(4):26. doi: 10.3390/medicines9040026. Note: Approved by the ESMO Guidelines Committee: July 2017, last update October 2022. . The median patient age was 56 years (range 1694 years). Only 2 women are Mongolians and the other 733 women are Asian Taiwanese. 28, 33233329. EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes. Furthermore, Moon et al. Bethesda, MD 20894, Web Policies (2007). ESMO is a Swiss-registered not-for-profit organisation. Cancer 104, 640643. Atopic patients are at increased risk for chemotherapy and MoAbs drug allergy and the current patterns of treatment with recurrent and intermittent drug exposures may favor the development of drug allergies. government site. Before desensitization; drug allergy; monoclonal antibodies in cancer; platins; taxanes. hypersensitivity and pneumonitis not otherwise specified. doi: 10.1111/j.1525-1438.2007.01063.x, Genc, D. B., Canpolat, C., and Berrak, S. G. (2012). Among cases developing carboplatin-related hypersensitivity reactions, the median number of cycles is 912, and the median doses 6,0008,000 mg. Reported risk factors for carboplatin-related hypersensitivity reactions include carboplatin cycle/dose, platinum-free interval, and history of drug allergies (Libra et al., 2003; Confino-Cohen et al., 2005; Schwartz et al., 2007; Koshiba et al., 2009). Hypersensitivity reactions are generally unexpected, regulated by the immune system, and allergic in nature. doi: 10.1093/annonc/mdt333. eCollection 2022. (2013). doi: 10.1007/s10147-014-0731-1. Therefore, the preferred regimen for platinum-sensitive recurrent ovarian cancer is carboplatin combined with paclitaxel, liposomal doxorubicin, or gemcitabine. Gynecol. Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies. doi: 10.1002/pbc.25697, Siegel, R. L., Miller, K. D., and Jemal, A. Int. Table 3. No use, distribution or reproduction is permitted which does not comply with these terms. Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin. This was the largest series of gynecological malignancies investigated for carboplatin-related hypersensitivity reactions. Lancet 361, 20992106. The annual incidence of carboplatin-related hypersensitivity reactions gradually increased from 0.88% in 2006 to 5.42% in 2013. The imaging findings follow the American Thoracic Society and European Respiratory Society classification of interstitial pneumonia. Assess for pustules or blisters or erosions in addition to areas of "dusky erythema" which may feel painful to palpation. doi: 10.1016/j.ygyno.2016.09.027, Bruchim, I., Goldberg, A., Fishman, A., and Confino-Cohen, R. (2014). The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management. doi: 10.1200/JCO.1999.17.4.1141, Moon, D. H., Lee, J. M., Noonan, A. M., Annunziata, C. M., Minasian, L., Houston, N., et al. The annual incidence of carboplatin-related hypersensitivity reactions in 735 women with ovarian, fallopian tube, or primary peritoneal cancers. Unable to load your collection due to an error, Unable to load your delegates due to an error. (2010). A history of drug or food allergy, the presence of malignant ascites, and the cumulative carboplatin dose are three independent predictive factors of carboplatin hypersensitivity in this survey. Analysis and interpretation of data: Y-HT, Y-JT, H-CH, Y-YC, and W-FC. Model of in vitro mouse mast cells activation and desensitization. Ann. A prospective single-center study. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). Virtually all chemotherapeutic agents have the potential to initiate infusion reactions, defined in this review as unexpected reactions that cannot be explained by the known toxicity profile of the drug. ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. This patient developed hypersensitivity reactions during her 23rd cycle of carboplatin administration at a cumulative dose of approximately 14,000 mg. She experienced skin rash, tachycardia, and dyspnea 13 min after starting the infusion. In an era of deep understanding of the molecular biology underlying the development of cancer, it is crucial that researchers and clinicians exchange knowledge. Cancer 15, 1318. All funding for this site is provided directly by ESMO. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C., et al. This site uses cookies. Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two TRYPHAENA arms: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. 8:800. doi: 10.3389/fphar.2017.00800. Abe, A., Ikawa, H., and Ikawa, S. (2010). The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Supportive and Palliative Care | ESMO Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines Published in 2017 - Ann Oncol (2017) 28 (suppl 4): iv100-iv118. Necessary cookies enable core functionality. Patients should be observed closely for hypersensitivity reactions for a minimum of 30 minutes following each IV iron . Oncol. 2011 Aug;12(8):806-14. doi: 10.1016/S1470-2045(10)70208-4. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. We also provide recommendations for the continuation of treatment in ovarian cancer patients. We also recorded the procedures applied to treat the hypersensitivity reactions and efforts to manage the side effects of carboplatin administration. Open. Among these 75 women, 16 (21.3%) experienced severe hypersensitivity reactions (grades 3 and 4). Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. These ESMO Clinical Practice Guidelines provide recommendations on the prevention/management of dermatological toxicities. Please enable it to take advantage of the complete set of features! Ann Oncol. Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients. The experience from Women and Infants' Hospital. For more detailed information on the cookies we use, please check our Privacy Policy. and transmitted securely. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (2009) reported the successful re-treatment of the majority of patients with previous carboplatin-related hypersensitivity reactions. Utilizing Biologics in Drug Desensitization. 144, 7782. Lacouture, V. Sibaud, P.A. (2010). All funding for this site is provided directly by ESMO. Prior to an infusion of a mAb, nurses should do the following (Olsen et al., 2019): . Supporting your clinical decisions with ESMOs regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession. Among the 651 women (88.6%) diagnosed with ovarian cancer, 474 (64.5%) had stage IIIIV disease. To overcome drug allergy, desensitization has been developed, a novel approach which provides a unique opportunity to protect against anaphylaxis and to improve clinical outcomes. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. DARMSTADT, Germany, August 31, 2017 /PRNewswire/ --Not intended for U.K. or U.S. based media ESMO 2017 abstract #Erbitux: 576P, 593P, 1068P, 1579. Critical revision: C-AC. doi: 10.1093/annonc/mdy158. de Las Vecillas Snchez L, Alenazy LA, Garcia-Neuer M, Castells MC. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. doi: 10.1200/JCO.2009.25.7519, Schwartz, J. R., Bandera, C., Bradley, A., Brard, L., Legare, R., Granai, C. O., et al. reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions [1]. (2006). Carboplatin-related hypersensitivity reactions sometimes result in premature discontinuation of treatment (Schwartz et al., 2007). Algorithm for the evaluation of drug hypersensitivity reactions and the role of desensitization for the re-introduction of the first-line medications, when no alternative is available or the alternative does not provide the same benefits or life expectancy as the first line. Tx-nave pts ORR was 90%. The incidence of severe carboplatin-related hypersensitivity reactions ranges from 2 to 6%, with the lowest incidence occurring in our study. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. eCollection 2022. 2017;40(3):120-127. doi: 10.1159/000458443. Supportive. (Bruchim et al., 2014) demonstrated safe re-treatment with carboplatin using a desensitization protocol to reduce repeated hypersensitivity reactions, and Koshiba et al. PMC However, other studies have reported severe hypersensitivity reactions to cisplatin in patients with prior carboplatin hypersensitivity reactions (Zweizig et al., 1994; Dizon et al., 2002). doi: 10.1093/annonc/mdx216. Genc et al. 24, 2432. doi: 10.1159/000055363, Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., et al. http://downloads.hindawi.com/journals/mbd/2010/207084.pdf, Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. A spotlight on alkaloid nanoformulations for the treatment of lung cancer. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Multivariate analysis was conducted using logistic regression to estimate the association between the potential risk factors and the occurrence of hypersensitivity. The tests were analyzed at an accredited lab according to protocol. Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations Front Immunol. As shown in Table 6, drug or food history (odd ratios [OR] 2.340, 95% confidence interval [CI] 1.374-3.984, P = 0.0018), malignant ascites (OR 1.895, 95% CI 1.1083.241, P = 0.0196), and cumulative carboplatin dose (4,0004,999 mg: OR 5.507, 95% CI 1.79616.887, P = 0.0028; 5,0009,999 mg: OR 7.244, 95% CI 2.74019.149, P < 0.0001; 10,000 mg: OR 8.461, 95% CI 3.00723.806, P < 0.0001; P for trend < 0.0001) significantly positively correlated with carboplatin hypersensitivity. Our results revealed carboplatin-related hypersensitivity reactions in 1 out of 10 women treated with a carboplatin-containing regimen for ovarian, fallopian tube, or primary peritoneal cancer. The essential content of the guidelinesin condensed slide format in PDF or PowerPoint. Department of Pharmacological and Biomolecular Sciences, Faculty of Pharmacy, University of Milan, Italy, Ospedale Oncologico Armando Businco, Italy, University of Arkansas for Medical Sciences, United States. Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. A video magazine about the congress, highlighting the most important information about the event. 2017 Jul 1;28(suppl_4):iv100-iv118. doi: 10.1016/S0140-6736(03)13718-X, Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., et al. Thus, we chose the cumulative carboplatin dose for the analysis to avoid interference between the highly correlated factors. The incidence of carboplatin-related hypersensitivity correlated with cycle number and dose, with the first episode occurring at a median of 12 cycles and 6,816 mg. Metrics. Cancer statistics, 2016. The yearly incidence of carboplatin-related hypersensitivity gradually increased from 0.88 in 2006 to 5.42% in 2013 (Table 1), in association with increased use of carboplatin. doi: 10.1006/gyno.1994.1098, Keywords: ovarian cancer, chemotherapy, carboplatin, hypersensitivity, risk factor, Citation: Tai Y-H, Tai Y-J, Hsu H-C, Lee S-P, Chen Y-Y, Chiang Y-C, Chen Y-L, Chen C-A and Cheng W-F (2017) Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. Oncol. Summary format including algorithms, figures andtables for your presentations. Unauthorized use of these marks is strictly prohibited. Oncol. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Women are more affected by drug allergy and up to 27% of women with ovarian and breast cancer develop carboplatin allergy after multiple cycles of treatment. Epub 2012 May 3. 57, 163167. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. This site needs JavaScript to work properly. Libra, M., Sorio, R., Buonadonna, A., Berretta, M., Stefanovski, P., Toffoli, G., et al. By delivering the target dose of the drug by small incremental doubling doses (Figure 3), the threshold for anaphylaxis is re-established at each step and never reaches that of the initial triggering dose. Yamamoto A, Kamoi S, Matsuda S, Kawase R, Nakanishi K, Suzuki S. Medicines (Basel). | DOI: 10.1097/HS9.0000000000000695. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. (2003). An official website of the United States government. The .gov means its official. ESMO Clinical Practice Guidelines: Supportive and Palliative Care, ESMO Clinical Practice Guidelines on Palliative Care: Advanced Care Planning, Clinical Practice Guideline Anxiety and Depression, Anaemia and Iron Deficiency in Patients With Cancer, Clinical Practice Guidelines Management of Anaemia and Iron deficiency, Clinical Practice Guidelines Bone Health in Cancer Patients, Clinical Practice Guidelines Cancer Cachexia in Adult Patients, Clinical Practice Guidelines Management of cancer pain, Clinical Practice Guidelines - Cancer-related Fatigue, Clinical Practice Guidelines Care at the End of Life, Central Venous Access in Oncology: ESMO Clinical Practice Guidelines, Management of Chemotherapy Extravasation: ESMO Clinical Practice Guidelines, Clinical Practice Guidelines Constipation in advanced cancer, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions.